{"id":"W2600744694","doi":"10.1200/jco.2013.31.15_suppl.5515","title":"A multicenter open-label phase II study of the efficacy and safety of ganitumab (AMG 479), a fully human monoclonal antibody against insulin-like growth factor type 1 receptor (IGF-1R) as second-line therapy in patients with recurrent platinum-sensitive ovarian cancer.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Growth Hormone and Insulin-like Growth Factors","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"ca_institutions":"Hôpital Notre-Dame; Ontario Clinical Oncology Group","funders":"","keywords":"Medicine; Internal medicine; Clinical endpoint; Asymptomatic; Progression-free survival; Hazard ratio; Nausea; Phases of clinical research; Oncology; Gastroenterology; Confidence interval; Clinical trial; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002247165,0.001530235,0.002140177,0.0003998044,0.000430812,0.0009721229,0.0008988484,0.001229874,0.00301418],"category_scores_gemma":[0.001414174,0.0006579537,0.001005727,0.0004169114,0.001629411,0.001255839,0.0003948776,0.002714536,0.0008062507],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001348066,"about_ca_system_score_gemma":0.001648697,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009984856,"about_ca_topic_score_gemma":0.001853108,"domain_scores_codex":[0.9993629,0.0003471893,0.00002780746,0.00012248,0.00004676576,0.00009286081],"domain_scores_gemma":[0.9986675,0.0002144022,0.0003003699,0.0001296832,0.00005983024,0.0006281495],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8409597,0.06744204,0.01056266,0.0003582927,0.000877536,0.0002306143,0.000271047,0.001776457,0.02555727,0.0001997436,0.002632753,0.04913205],"study_design_scores_gemma":[0.54277,0.4379228,0.01410306,0.00001576077,0.0002699075,0.0002657488,0.00005250701,0.001399119,0.00179953,0.0001487482,0.001232346,0.00002047137],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9949297,0.0009287929,0.0005050556,0.0002466331,0.00008650307,0.001790322,0.0007128661,0.00006851739,0.000731552],"genre_scores_gemma":[0.9924154,0.0006249765,0.001400756,0.0005733636,0.0001811162,0.001921819,0.001820313,0.00002749973,0.001034686],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00301418,"threshold_uncertainty_score":0.01188433,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07820653171816491,"score_gpt":0.4206150454328463,"score_spread":0.3424085137146814,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}